Syngene International signs 10-year agreement with US-based firm Zoetis

Librela or bedinvetmab has already been launched in Europe and the UK, and has won 'Best new companion animal product' by IHS Markit Connect in 2021

Biocon arm Syngene International has signed a 10-year agreement to manufacture the drug substance for Librela, a monoclonal antibody used to treat osteoarthritis in dogs, with US-based animal health company Zoetis.

The collaboration with Zoetis started in 2011 and over the past 11 years, Syngene has undertaken development work on several monoclonal antibodies for use in animal health, including developing and manufacturing clinical supplies of a treatment for allergic or atopic dermatitis, and Librela.

“This agreement, initially centred on Librela, paves the way for development and manufacturing of other molecules in the coming years and is expected to be worth